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Introduction: Cystic ﬁbrosis (CF) is the most common lethal autosomal recessive
disease among Caucasians and is due to a mutation in the CF Transmembrane
Regulator (CFTR). The main mutation is a deletion at amino acid 508. Due to
an increase in life expectancy, new complications such as Cystic Fibrosis Related
Diabetes (CFRD) have emerged. CFRD is primary due to defect in insulin secretion.
Studies have shown that women and DF508/DF508 mutation have a higher risk of
developing CFRD.
Objectives: Compare insulin secretion between CF men and women with different
genotypes.
Methods: Two hundreds non-diabetic adult subjects were recruited from the CF
clinic of the CHUM. Genotype status was extracted from the medical ﬁles. All
subjects underwent a 2 h Oral Glucose Tolerance Test (OGTT) to determine their
glucose tolerance: normal glucose tolerance (NGT), impaired glucose tolerance
(IGT) or CFRD. Blood samples were taken every 30 min. From this samples insulin
secretion and sensitivity were evaluated using Stumvoll indices derived from OGTT.
Results: For a comparable glucose excursion there were gender and genetic
differences in insulin values during the OGTT. Heterozygous patients have higher
insulinemia than those with the homozygous mutation. Whatever their glucose
tolerance and genotype, women present a higher insulinemia than men. Calculation
of the disposition index (insulin secretion adjusted for the degree of insulin
sensitivity) conﬁrmed the higher insulin secretion in women.
Conclusion: We report for the 1st time a higher insulin secretion in women CF
subjects, the role of this observation for their known increase risk for CFRD deserve
further studies.
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Objectives: New onset diabetes after transplantation (NODAT) becomes more
prominent due to increased survival.
Aim of our study was to create an incidence curve of NODAT for lung trans-
plantation (LTx) recipients with and without CF and to determine the effect of
pretransplant diabetes on survival after LTx.
Methods: All patients we transplanted in 2001–2009 were included. Using the
guideline of the American Diabetes Association diabetes was diagnosed in case of
(a) glucose lowering drugs or (b) fasting glucose 7.0 or 2 h glucose 11.1mmol/l
during an OGTT or (c) 2 separate days fasting 7.0 or random glucose
11.1mmol/l. Diagnosis could only be determined in a period without infection,
with stable use of corticosteroids and before or 3 months after LTx.
Results: 40 CF (28 male) and 35 non-CF patients (14m) were included. CF patients
were signiﬁcantly younger (mean age 31; non-CF 54y) and had a lower BMI (mean
BMI 19.4; non-CF 23.4kg/m2, p< 0.001). Before LTx 62% of CF and 6% of non-
CF patients had diabetes (p< 0.001, adjusted for age, sex, BMI). In both groups the
same number of patients developed diabetes after LTx, mainly in ﬁrst year after LTx
(p = 0.9, CF 62%, 8 of 13 patients at risk and non-CF 67%, 18/27 patients). In the
CF group, patients without diabetes before LTx had a signiﬁcantly better survival
(p = 0.015). These groups were similar for age, BMI, high urgency indication and
mutation severity.
Conclusion: Before LTx more CF patients than non CF patients had diabetes. After
LTx the number of patients in both groups developing NODAT was similar (~65%).
CF patients without diabetes before LTx had signiﬁcantly longer survival than those
with diabetes.
313* An audit of long term complication screening for
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Introduction: With increasing cystic ﬁbrosis (CF) survival, CFRD and its compli-
cations are becoming more common, and the UK CF Trust guidelines suggest that
such patients are screened annually for complications. Whilst this can be carried
out in primary care or by a non-CF diabetes clinic, in order to deliver specialised
holistic care and avoid conﬂicting information from general diabetes healthcare
practitioners, we undertake an in-house CFRD complication screening program at
our large regional adult CF unit, where 94 patients (36%) have CFRD.
Method: We screened 68 (72%) using a protocol including HBa1C, cholesterol,
LFTs, microalbuminuria, and injection sites, peripheral neuropathy, and blood
pressure check. Patients were also asked to attend for a local eye screen and in
those who were drivers whether the vehicle licensing agency had been informed
about their insulin use.
Results: Twelve (18%) had an elevated HBa1C, 3 a high cholesterol, and 17
(25%) raised LFTs. Eleven (16%) had signiﬁcant microalbuminuria (a further 5
were unchecked due to continuous IV antibiotic use). Six (9%) had lipodystrophy,
and 1 peripheral neuropathy. Eye screening results were known in 22 (32%), of
which 5 had developed proliferative retinopathy requiring treatment. Finally, out
of 52 drivers, 19 (33%) had not informed the vehicle licensing authority that they
required insulin.
Conclusion: This study shows the worsening complication rate associated with
CFRD as patients live longer and its prevalence increases. Annual screens for
CFRD complications are important and a formal process should be adopted by all
adult CF units, to improve the care of this growing subgroup of adult CF patients.
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Background: Microalbuminuria is a sensitive marker of early renal damage in non-
CF diabetes. Although its use in CFRD has been questioned since other factors
in CF may inﬂuence the results, there is a paucity of data and studies have only
assessed small patient numbers. To look at this further, we correlated the occurrence
of microalbuminuria with clinical features in a group of 52 adults with CFRD.
Methods: We routinely test for microalbuminuria in our adult CFRD patients at
their annual screen. The clinical characteristics (nutritional state, lung function,
duration of CFRD, HbA1C, use of nephrotoxic drugs, and IV antibiotics) of
6 patients with persistent microalbuminuria were compared with 46 without this
complication.
Results: See table.
Microalbuminuria Persistent (n = 6) None (n = 46) P value
Age, years 22.5 (21−24) 25 (21−32) 0.42
BMI (kg/m2) 22.3 (21.8–23.5) 21.9 (20.5–25.4) 0.85
FEV1 % predicted 77 (53–100) 57.5 (43−71) 0.17
Known duration of CFRD, years 6 (4−14) 3 (2−5) 0.07
HbA1C (%) 8.7 (7.4−9.2) 6.1 (5.7−6.7) 0.02
IV antibiotics (days over last 2 years) 21 (14–150) 39.5 (21−88) 0.63
Use of nephrotoxic drugs
Azithromycin 6 (100) 38 (82.6) 0.57
Tobramycin 3 (50) 24 (52.2) >0.99
Colomycin 5 (83.3) 36 (78.3) >0.99
Categorical variables − n (%), Fisher’s exact test; Continuous variables − median (IQR),
Wilcoxon signed rank test.
Conclusion: In our cohort, persistent microalbuminuria was associated with sub-
optimal glycaemic control and there was a trend towards length of CFRD. The fact
that it was not related to other clinical parameters suggests that it may be a sensitive
screening tool for renal microvascular complications in CFRD.
